Drug intelligence / Profile preview

CB5064

Development stage: Preclinical
Lead developer: CohBar
Modality: Peptides
Administration: Subcutaneous

Overview

**CB5064** is a mitochondrially encoded peptide developed by CohBar as the basis for analogs targeting metabolic and inflammatory diseases. It acts as an agonist of the apelin receptor (APJ/APLNR), promoting effects such as body weight reduction, improved glucose tolerance, and insulin sensitivity in preclinical models of diet-induced obesity. Analogs have also demonstrated efficacy in reducing lung fluid accumulation, neutrophil infiltration, and pro-inflammatory cytokines in models of acute lung injury and acute respiratory distress syndrome (ARDS), including COVID-19-associated ARDS.[1][2][4][7]

Targets

APLNR (Apelin receptor)

Beyond the preview

Go deeper on CB5064.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB5064.

Explore the full profile